Technology rights are related to role of FOX gene expression.
DiagnoCure acquired specific rights and commissioned further research on new genes that show promise as prostate cancer markers. The agreement, signed with Radboud University Medical Center, Nijmegen, the Netherlands, covers technology rights related to Dr. Jack Schalken’s discoveries of the role of FOX gene expression in prostate cancer and commissions further research into the diagnostic, prognostic, and therapeutic potential of those genes.

“We have sufficient evidence to indicate that specific FOX genes may further enhance the diagnostic efficacy of the PCA3 gene, which in itself reflects a dramatic improvement over PSA testing,” asserts Dr. Schalken.

Previous articleBeckman Coulter Secures Lumigen for $185M
Next articleOncalis and ChemDiv Tackle Cancer-related Kinase Targets